ALK and non-small cell lung carcinoma: Extensive prognostic and predictive biomarkers, such as ALK, mesenchymal-epithelial transition factor (c-MET), and ROS1, are identified by FISH.82 Significantly, the timeless and costless FISH remains a gold standard in ALK-rearrangements NSCLC.83 In 2011, a novel anticancer drug crizotinib and its companion, the ALK FISH probe detection kit, were simultaneously approved by the FDA, which highlights the crucial position of the FISH assay in guiding ALK-targeted therapy.84